Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Core Insights - Emergent BioSolutions Inc. has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for approximately $36.5 million, subject to customary post-closing adjustments [1][2] - The sale allows Emergent to streamline operations while retaining rights to secure manufacturing services and capacity at the facility for future growth and pandemic response production in collaboration with Syngene [2][3] - The CEO of Emergent stated that this deal positions the company well for executing turnaround initiatives and driving sustainable, long-term growth [3] Company Overview - Emergent BioSolutions has been active for over 25 years, focusing on delivering protective and life-saving solutions for various health threats, including smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies [4]